DICE Therapeutics, Inc.
DICE · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.32 | -0.02 | -0.44 | 0.00 |
| FCF Yield | -5.41% | -12.76% | -2.43% | -2.02% |
| EV / EBITDA | -9.41 | -4.21 | -34.83 | -69.52 |
| Quality | ||||
| ROIC | -14.80% | -14.94% | -43.41% | -49.19% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.77 | 0.80 | 0.87 | 1.26 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -42.03% | 951,973.04% | 1,794,016.59% |
| Free Cash Flow Growth | -66.36% | -92.11% | -20.53% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 5.40 | 2.39 | 2.60 | 0.68 |
| Interest Coverage | -129.93 | -273.58 | -1,824.69 | -521.04 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 648.89 | 845.89 | 126.41 |